Fatty acid oxidation and isoprostanes: Oxidative strain and oxidative stress

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 82, Issue 4-6, 2010, Pages 219-225

  Basu, Samar ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBON TETRACHLORIDE; FREE RADICAL; ISOPROSTANE; ISOPROSTANE DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; CIGARETTE SMOKING; CIRCADIAN RHYTHM; CONCENTRATION (PARAMETERS); DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; ESSENTIAL HYPERTENSION; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY DIAGNOSIS; LIPID PEROXIDATION; LIVER INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHYSIOLOGICAL PROCESS; PREGNANCY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN URINE LEVEL;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FATTY ACIDS; FEMALE; HUMANS; ISOPROSTANES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PREGNANCY;

EID: 77951975399     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2010.02.031     Document Type: Article

References (80)

1. Droge W. Free radicals in the physiological control of cell function. Physiological Reviews 2002, 82:47-95.
2. Finkel T. Oxygen radicals and signaling. Current Opinion in Cell Biology 1998, 10:248-253.
3. Finkel T. Reactive oxygen species and signal transduction. IUBMB Life 2001, 52:3-6.
4. Finkel T. Oxidant signals and oxidative stress. Current Opinion in Cell Biology 2003, 15:247-254.
5. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxidant & Redox Signaling 2008, 10:1405-1434.
6. Bogdan C. Nitric oxide and the regulation of gene expression. Trends in Cell Biology 2001, 11:66-75.
7. Ishihara O., Hayashi M., Osawa H., et al. Isoprostanes, prostaglandins and tocopherols in pre-eclampsia, normal pregnancy and non-pregnancy. Free Radical Research 2004, 38:913-918.
8. Palm M., Axelsson O., Wernroth L., Basu S. F(2)-isoprostanes, tocopherols and normal pregnancy. Free Radical Research 2009, 43:546-552.
9. Helmersson J., Basu S. F2-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins, Leukotrienes, and Essential Fatty Acids 1999, 61:203-205.
10. Helmersson J., Basu S. F(2)-isoprostane and prostaglandin F(2 alpha)metabolite excretion rate and day to day variation in healthy humans. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2001, 65:99-102.
11. Basu S., Helmersson J. Factors regulating isoprostane formation in vivo. Antioxidants & Redox Signaling 2005, 7:221-235.
12. Basu S. Novel cyclooxygenase-catalyzed bioactive prostaglandin F(2alpha) from physiology to new principles in inflammation. Medicinal Research Reviews 2007, 27:435-468.
13. Serhan C.N. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2005, 73:141-162.
14. Basu S. Isoprostanes: novel bioactive products of lipid peroxidation. Free Radical Research 2004, 38:105-122.
15. Basu S. The enigma of in vivo oxidative stress assessment: isoprostanes as an emerging target. Scandinavian Journal of Food and Nutrition 2007, 51:48-61.
16. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408:239-247.
17. Nemoto S., Finkel T. Ageing and the mystery at Arles. Nature 2004, 429:149-152.
18. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
19. Zethelius B., Berglund L., Sundstrom J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. The New England Journal of Medicine 2008, 358:2107-2116.
20. In: H. Sies (Ed.), Oxidative Stress: Introductory Remarks, Academic Press, London, 1985, pp. 1-8.
21. Morrow J.D. The isoprostanes - unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Current Pharmaceutical Design 2006, 12:895-902.
22. Morrow J.D., Roberts L.J. The isoprostanes. Current knowledge and directions for future research. Biochemical Pharmacology 1996, 51:1-9.
23. Montuschi P., Barnes P., Roberts L.J. Insights into oxidative stress: the isoprostanes. Current Medicinal Chemistry 2007, 14:703-717.
24. 4 poisoning?. Free Radical Biology & Medicine 2005, 38:698-710.
25. 4 poisoning. Free Radical Biology & Medicine 2005, 38:711-718.
26. Nugteren D.H., Vonkeman H., Van Dorf D.A. Non-enzymatic conversion of all cis-8,11,14-eicosatrienoic acid into PGE1. Recueil des Travaux Chimiques des Pays-Bas 1967, 86:1237-1245.
27. Porter N.A., Funk M.O. Letter: peroxy radical cyclization as a model for prostaglandin biosynthesis. Journal of Organic Chemistry 1975, 40:3614-3615.
28. Morrow J.D., Awad J.A., Kato T., et al. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. The Journal of Clinical Investigation 1992, 90:2502-2507.
29. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., Roberts L.J.d A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:9383-9387.
30. Morrow J.D. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metabolism Reviews 2000, 32:377-385.
31. Roberts L.J., Morrow J.D. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radical Biology & Medicine 2000, 28:505-513.
32. Morrow J.D., Awad J.A., Boss H.J., Blair I.A., Roberts L.J. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:10721-10725.
33. Basu S. Metabolism of 8-iso-prostaglandin F2alpha. FEBS Letters 1998, 428:32-36.
34. Chiabrando C., Valagussa A., Rivalta C., et al. Identification and measurement of endogenous beta-oxidation metabolites of 8-epi-prostaglandin F2alpha. The Journal of Biological Chemistry 1999, 274:1313-1319.
35. Roberts L.J., Moore K.P., Zackert W.E., Oates J.A., Morrow J.D. Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2alpha in humans. The Journal of Biological Chemistry 1996, 271:20617-20620.
36. Basu S. Radioimmunoassay of 8-iso-prostaglandin F2alpha: an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins, Leukotrienes, and Essential Fatty Acids 1998, 58:319-325.
37. Basu S., Riserus U., Turpeinen A., Vessby B. Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity. Clinical Science (London) 2000, 99:511-516.
38. Richelle M., Turini M.E., Guidoux R., Tavazzi I., Metairon S., Fay L.B. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Letters 1999, 459:259-262.
39. Wang Z., Ciabattoni G., Creminon C., et al. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. The Journal of Pharmacology and Experimental Therapeutics 1995, 275:94-100.
40. Bachi A., Zuccato E., Baraldi M., Fanelli R., Chiabrando C. Measurement of urinary 8-epi-prostaglandin F2alpha, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry. Basal levels in smokers and non-smokers. Free Radical Biology & Medicine 1996, 20:619-624.
41. Ide T., Tsutsui H., Ohashi N., et al. Greater oxidative stress in healthy young men compared with premenopausal women. Arteriosclerosis, Thrombosis, and Vascular Biology 2002, 22:438-442.
42. Helmersson J., Mattsson P., Basu S. Prostaglandin F(2alpha) metabolite and F(2)-isoprostane excretion rates in migraine. Clinical Science (London) 2002, 102:39-43.
43. Schraag S., Mandach U., Schweer H., Beinder E. Metabolic changes, hypothalamo-pituitary-adrenal axis and oxidative stress after short-term starvation in healthy pregnant women. Journal of Perinatal Medicine 2007, 35:289-294.
44. Gutteridge J.M., Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends in Biochemical Sciences 1990, 15:129-135.
45. Basu S., Helmersson J. Bioactive isoprostanes. New markers of oxidative stress and inflammation-related diseases. Lakartidningen 2009, 106:274-278.
46. Lawson J.A., Rokach J., FitzGerald G.A. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. The Journal of Biological Chemistry 1999, 274:24441-24444.
47. Basu S. Oxidative injury induced cyclooxygenase activation in experimental hepatotoxicity. Biochemical and Biophysical Research Communications 1999, 254:764-767.
48. Sodergren E., Cederberg J., Vessby B., Basu S. Vitamin E reduces lipid peroxidation in experimental hepatotoxicity in rats. European Journal of Nutrition 2001, 40:10-16.
49. Gopaul N.K., Halliwell B., Anggard E.E. Measurement of plasma F2-isoprostanes as an index of lipid peroxidation does not appear to be confounded by diet. Free Radical Research 2000, 33:115-127.
50. H. Petersson, U. Risérus, J. McMonagle, A.C. Tierney, J. Lovegrave, S. Morange, O. Helal, H.L. Gulseth, J.A. Ruano, J. Lopez-Miranda, A. Dembinska-Kiec, E. Blaak, I.M.F. Gjeldstad, C.A. Drevon, H. Roche, S. Basu, Effects of dietary fat modification on oxidative stress and inflammatory markers in the LIPGENE study, British Journal of Nutrition (2009), under review.
51. Sodergren E., Cederberg J., Basu S., Vessby B. Vitamin E supplementation decreases basal levels of F(2)-isoprostanes and prostaglandin F(2alpha) in rats. The Journal of Nutrition 1999, 130:10-14.
52. Sodergren E., Vessby B., Basu S. Radioimmunological measurement of F(2)-isoprostanes after hydrolysis of lipids in tissues. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2000, 63:149-152.
53. DeGraba T.J. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology 1997, 49:S15-S19.
54. Basu S., Larsson A., Vessby J., Vessby B., Berne C. Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. Diabetes Care 2005, 28:1371-1375.
55. Helmersson J., Larsson A., Vessby B., Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis 2005, 181:201-207.
56. Helmersson J., Vessby B., Larsson A., Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004, 109:1729-1734.
57. Sinaiko A.R., Steinberger J., Moran A., et al. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors, and oxidative stress during adolescence. Circulation 2005, 111:1985-1991.
58. Wohlin M., Helmersson J., Sundstrom J., et al. Both cyclooxygenase- and cytokine-mediated inflammation are associated with carotid intima-media thickness. Cytokine 2007, 38:130-136.
59. Ockene I.S., Miller N.H. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association task force on risk reduction. Circulation 1997, 96:3243-3247.
60. Morrow J.D., Frei B., Longmire A.W., et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. The New England Journal of Medicine 1995, 332:1198-1203.
61. Ahmadzadehfar H., Oguogho A., Efthimiou Y., Kritz H., Sinzinger H. Passive cigarette smoking increases isoprostane formation. Life Sciences 2006, 78:894-897.
62. Basu S., Helmersson J., Jarosinska D., Sallsten G., Mazzolai B., Barregard L. Regulatory factors of basal F(2)-isoprostane formation: population, age, gender and smoking habits in humans. Free Radical Research 2009, 43:85-91.
63. Davi G., Ciabattoni G., Consoli A., et al. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999, 99:224-229.
64. Davi G., Chiarelli F., Santilli F., et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003, 107:3199-3203.
65. Gleisner A., Martinez L., Pino R., et al. Oxidative stress markers in plasma and urine of prepubertal patients with type 1 diabetes mellitus. Journal of Pediatric Endocrinology & Metabolism 2006, 19:995-1000.
66. Hoeldtke R.D., Bryner K.D., McNeill D.R., Warehime S.S., Van Dyke K., Hobbs G. Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. The Journal of Clinical Endocrinology and Metabolism 2003, 88:1624-1628.
67. O'Byrne S., Forte P., Roberts L.J., et al. Nitric oxide synthesis and isoprostane production in subjects with type 1 diabetes and normal urinary albumin excretion. Diabetes 2000, 49:857-862.
68. Vessby J., Basu S., Mohsen R., Berne C., Vessby B. Oxidative stress and antioxidant status in type 1 diabetes mellitus. Journal of Internal Medicine 2002, 251:69-76.
69. Gopaul N.K., Anggard E.E., Mallet A.I., Betteridge D.J., Wolff S.P., Nourooz-Zadeh J. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Letters 1995, 368:225-229.
70. Gopaul N.K., Manraj M.D., Hebe A., et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 2001, 44:706-712.
71. Murai Y., Hishinuma T., Suzuki N., Satoh J., Toyota T., Mizugaki M. Determination of urinary 8-epi-prostaglandin F(2alpha) using liquid chromatography-tandem mass spectrometry: increased excretion in diabetics. Prostaglandins & Other Lipid Mediators 2000, 62:173-181.
72. Davi G., Di Minno G., Coppola A., et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001, 104:1124-1128.
73. Cracowski J.L., Baguet J.P., Ormezzano O., et al. Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension. Hypertension 2003, 41:286-288.
74. Minuz P., Patrignani P., Gaino S., et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002, 106:2800-2805.
75. Lopes H.F., Martin K.L., Nashar K., Morrow J.D., Goodfriend T.L., Egan B.M. DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity. Hypertension 2003, 41:422-430.
76. Ward N.C., Hodgson J.M., Puddey I.B., Mori T.A., Beilin L.J., Croft K.D. Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radical Biology & Medicine 2004, 36:226-232.
77. Cracowski J.L., Cracowski C., Bessard G., et al. Increased lipid peroxidation in patients with pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2001, 164:1038-1042.
78. Urakawa H., Katsuki A., Sumida Y., et al. Oxidative stress is associated with adiposity and insulin resistance in men. The Journal of Clinical Endocrinology and Metabolism 2003, 88:4673-4676.
79. K.M. Pou, J.M. Massaro, U. Hoffmann, et al., Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress. The Framingham heart study, Circulation (2007).
80. Davi G., Guagnano M.T., Ciabattoni G., et al. Platelet activation in obese women: role of inflammation and oxidant stress. Journal of the American Medical Association 2002, 288:2008-2014.